BUZZ-Arvinas falls after Leerink's price target cut

Reuters03-21

** Shares of drug developer Arvinas ARVN.O fall 3.4% to $8.70

** Brokerage Leerink lowers PT to $12 from $49, maintains "outperform" rating

** Despite disappointing topline results for vepdegestrant, staying the course and remaining outperform pending detailed data release and visibility on a number of key value levers - Leerink

** Vepdegestrant, ARVN and Pfizer's PFE.N oral drug, failed to delay progression of breast cancer in patients with most common type of the disease in a late-stage trial last week

** It is too early to assume that vepdeg is inferior to elacestrant, as the failure in the intention-to-treat population could have been driven by a number of factors - brokerage

** Elacestrant is used to treat certain types of hormone receptor-positive breast cancer

** As of last close, ARVN down 53% YTD

(Reporting by Juby Babu in Mexico City)

((Juby.Babu@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment